These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16869787)

  • 41. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and economic review of erlotinib in non-small-cell lung cancer.
    Yeung K; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
    Pennell NA; Yin L; Keshtgarpour M; Ma PC
    J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
    [No Abstract]   [Full Text] [Related]  

  • 44. Recent developments related to the EGFR as a target for cancer chemotherapy.
    Speake G; Holloway B; Costello G
    Curr Opin Pharmacol; 2005 Aug; 5(4):343-9. PubMed ID: 15950538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.
    Politi K; Ayeni D; Lynch T
    Cancer Cell; 2015 Jun; 27(6):751-3. PubMed ID: 26058074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 47. Targeting EGFR in non-small-cell lung cancer.
    Doroshow JH
    N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
    [No Abstract]   [Full Text] [Related]  

  • 48. Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
    Achille M; Gallegos-Ruiz M; Giaccone G; Soria JC
    Clin Lung Cancer; 2006 Nov; 8(3):214-6. PubMed ID: 17239298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
    Sasaki H; Endo K; Mizuno K; Yano M; Fukai I; Yamakawa Y; Fujii Y
    Lung Cancer; 2006 Jan; 51(1):135-6. PubMed ID: 16314000
    [No Abstract]   [Full Text] [Related]  

  • 50. Erlotinib: optimizing therapy with predictors of response?
    Goodin S
    Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
    [No Abstract]   [Full Text] [Related]  

  • 51. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jänne PA
    Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554
    [No Abstract]   [Full Text] [Related]  

  • 52. Tailor-made chemotherapy for non-small cell lung cancer patients.
    Huang CL; Yokomise H; Fukushima M; Kinoshita M
    Future Oncol; 2006 Apr; 2(2):289-99. PubMed ID: 16563096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-line erlotinib inferior to chemo in advanced lung cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):930-1. PubMed ID: 23176004
    [No Abstract]   [Full Text] [Related]  

  • 54. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
    Langer CJ
    J Clin Oncol; 2009 Mar; 27(9):1350-4. PubMed ID: 19224840
    [No Abstract]   [Full Text] [Related]  

  • 55. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
    Apolone G; La Vecchia C; Garattini S
    Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
    [No Abstract]   [Full Text] [Related]  

  • 56. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
    Zalcman G
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
    [No Abstract]   [Full Text] [Related]  

  • 57. Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.
    Oncology (Williston Park); 2011 Nov; 25(12):1239-40. PubMed ID: 22229228
    [No Abstract]   [Full Text] [Related]  

  • 58. [New medications; erlotinib].
    Cohen AF; Dubois EA; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2703-4. PubMed ID: 17194007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
    Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
    [No Abstract]   [Full Text] [Related]  

  • 60. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.
    Yang SX; Simon RM; Tan AR; Nguyen D; Swain SM
    Clin Cancer Res; 2005 Sep; 11(17):6226-32. PubMed ID: 16144925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.